Evidence map›Paper›PMID 33122898›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2020

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT

Roland Buhl, Michael Dreher, Stephanie Korn, Christian Taube, Christian Stock, Christoph M Zehendner, Anke Kondla, Claus F Vogelmeier

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03954132 (EVELUT®), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03954132 completednot on this map

EVELUT®: Assessment of Dyspnea and Other Symptoms as Patient Reported Outcomes (PRO) in Patients With Chronic Obstructive Pulmonary Disease (COPD), Symptomatic on LABA/ICS Maintenance Therapy (Now) Treated With Spiolto® Respimat® (Tiotropium/Olodaterol) in Comparison to Open or Fixed Triple Combination Treatment in Routine Clinical Practice

TypeobservationalSponsorBoehringer IngelheimRan2019 to 2021Enrolled469ConditionsPulmonary Disease, Chronic ObstructiveArmsSpiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Beyond Dual Bronchodilation - Triple Therapy, When and Why.International journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Roland BuhlPulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany.
Michael DreherClinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
Stephanie KornPulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany.
Christian TaubeClinic for Pneumonology, University Medicine Essen - Ruhrlandklinik, Essen, Germany.
Christian StockBiostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.ORCID 0000-0002-3493-3234
Christoph M ZehendnerHP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Anke KondlaHP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.ORCID 0000-0002-1412-8510
Claus F VogelmeierDepartment of Pneumology, University Hospital of Giessen and Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.
Boehringer Ingelheim (Germany) · DEJohannes Gutenberg University Mainz · DERuhrlandklinik · DERWTH Aachen University · DEUniversitätsklinikum Gießen und Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Global Initiative for Chronic Obstructive Lung Disease 2020 report recommends that patients with chronic obstructive pulmonary disease (COPD) suffering from persistent dyspnea, despite long-acting β Methods: EVELUT Conclusion: EVELUT results are expected to add to the current real-world evidence informing therapeutic decisions for COPD in everyday clinical practice. Trial Registration: The European Union electronic Register of Post-authorisation Studies (EU PAS Register): EUPAS29784; the Federal Institute for Drugs and Medical Devices (BfArM): NIS Study No 7305; Clinicaltrials.gov: NCT03954132.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenergic beta-2 Receptor AgonistsBenzoxazinesBronchodilator AgentsDrug Therapy, CombinationHumansMulticenter Studies as TopicMuscarinic AntagonistsProspective StudiesTiotropium BromideAdrenergic beta-2 Receptor AgonistsBenzoxazinesBronchodilator AgentsMuscarinic AntagonistsolodaterolTiotropium BromideCOPDLAMA/LABA/ICSSpiolto® Respimat®tiotropium/olodateroltriple therapy

Identifiers

PMID33122898
PMCPMC7591229
OpenAlexW3094560769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.